Breaking News, Financial News

Financial Report: Johnson & Johnson

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson 2Q Revenues: $15.1 billion (+13%) 2Q Earnings: $3.1 billion (+9%) YTD Revenues: $30.2 billion (+15%) YTD Earnings: $5.7 billion (-8%) Comments: Worldwide Pharmaceutical sales were $6.1 billion in the quarter, up 5.8%. Topamax, Remicade, Risperdal, Risperdal Consta, Invega and Concerta contributed to this growth. In the quarter, the European Commission granted marketing authorization for Invega for the treatment of schizophrenia and the FDA approved an ad...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters